Douglas V. Faller
Papers
1
Total Citations
27
H-Index
1
About
Douglas V. Faller is a pioneering translational researcher whose work bridges molecular oncology, hemoglobinopathies, and cancer biology. His most impactful contributions center on the discovery and development of novel inducers of fetal globin for treating beta-hemoglobinopathies like sickle cell disease and beta-thalassemia. Using high-throughput screening of a LCR-γ-globin promoter-GFP reporter assay, Faller identified safe, orally-bioavailable compounds that reactivate fetal hemoglobin expression—a therapeutic strategy that can dramatically ameliorate disease severity. His landmark 2015 study demonstrated these agents are active in vivo in anemic baboons and transgenic mice, opening new avenues for non-toxic treatments. Beyond hemoglobin biology, Faller has made seminal contributions to understanding oncogene signaling, particularly the roles of Ras and protein kinase C in cancer progression, and has explored innovative approaches to cancer therapy including differentiation agents and gene regulation. With over 27 citations on his key fetal globin work and a career spanning decades of federally funded research, Faller’s work exemplifies bench-to-bedside science—identifying molecular targets, validating them in preclinical models, and advancing toward clinical applications that could transform care for millions of patients worldwide.
Research Focus
Key Achievements
Top Papers
- 1